Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at 2026 ESMO Annual Meeting
Innovent Biologics will present new clinical data on its upcoming cancer drug candidates at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting. The presentation will focus on the company's next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) pipeline.
Innovent Biologics will present new clinical data on its upcoming cancer drug candidates at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting. The presentation will focus on the company's next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) pipeline.
The company, headquartered in San Francisco and Suzhou, China, develops, manufactures, and commercializes medicines for oncology, cardiovascular, and metabolic diseases.
The data presented at the ESMO meeting are expected to support Innovent's efforts to expand its oncology drug portfolio with novel therapies targeting complex cancers.
According to the press release, the research findings will be crucial for the subsequent stages of Innovent's drug development.